Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
341 studies found for:    "Anaplastic large cell lymphoma"
Show Display Options
Rank Status Study
21 Completed Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
Condition: Large Cell Lymphoma
Intervention: Drug: SGN-30
22 Recruiting Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Condition: Anaplastic Large Cell Lymphoma, ALK-Positive
Intervention: Drug: crizotinib
23 Withdrawn MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Condition: Lymphoma, Large-Cell
Intervention: Drug: MDX-060
24 Active, not recruiting Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Other: pharmacogenomic studies;   Other: pharmacological study
25 Completed
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
26 Recruiting Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
Condition: ALCL
Intervention: Other: Blood sample
27 Recruiting Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Conditions: Hodgkin Disease;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: Brentuximab Vedotin
28 Completed Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Biological: monoclonal antibody HeFi-1
29 Recruiting AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma
Conditions: ALK Positive;   BCL6 Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Onalespib
30 Withdrawn Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Conditions: AIDS-related Lymphoma;   Adult Non-Hodgkin's Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: cisplatin;   Drug: cytarabine;   Drug: etoposide;   Drug: methylprednisolone;   Drug: rituximab;   Drug: yttrium Y 90 ibritumomab tiuxetan;   Procedure: antibody therapy;   Procedure: biological therapy;   Procedure: chemotherapy;   Procedure: monoclonal antibody therapy;   Procedure: radiation therapy;   Procedure: radioimmunotherapy;   Procedure: radioisotope therapy
31 Active, not recruiting ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Conditions: Anaplastic Large-Cell Lymphoma;   Non-Hodgkin Lymphoma;   T-Cell Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Drug: cyclophosphamide
32 Active, not recruiting Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: belinostat;   Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
33 Completed Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
34 Active, not recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma;   Mycosis Fungoides;   Cutaneous T-Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene
35 Recruiting Risk Stratification of Nodal PTCL
Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Angioimmunoblastic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-negative
36 Recruiting Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
Condition: Lymphoma
Intervention: Drug: Brentuximab Vedotin
37 Recruiting Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
38 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
39 Active, not recruiting A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, NK-cell;   Lymphoma, T-cell
Interventions: Drug: brentuximab vedotin;   Drug: cyclophosphamide;   Drug: prednisone;   Drug: doxorubicin;   Drug: vincristine
40 Unknown  Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: prednisone;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: pralatrexate;   Other: laboratory biomarker analysis;   Genetic: comparative genomic hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: RNA analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.